Reporting owner · CIK 0001595117

George Simeon

SEC Form 4 history for the last 180 days across 2 companies, 18 transactions and 2 filings.

DIRCRISPR Therapeutics AG
Open-market transaction mix75% buys3 buys · 1 sale

Period: Last 180 days

Trade dates in this period: Sep 28, 2026 – Oct 14, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings2Form 4 records
Buying$27.2M3 purchases
Selling$720k1 sale
Net value+$26.5MBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
George Simeon transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
CRSPCRISPR Therapeutics AG
Director
DIR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
CRSPCRISPR Therapeutics AG
Director
DIR
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$720kView disclosure →
CRSPCRISPR Therapeutics AG
Director
DIR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
$420kView disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
Derivative securitySEC filing ↗
$0View disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
Derivative securitySEC filing ↗
$0View disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
Derivative securitySEC filing ↗
$0View disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
Derivative securitySEC filing ↗
$0View disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
Derivative securitySEC filing ↗
$0View disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
Derivative securitySEC filing ↗
$0View disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$10.1MView disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
SEC filing ↗
—View disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
SEC filing ↗
—View disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$7.05MView disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
SEC filing ↗
—View disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$10.1MView disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
SEC filing ↗
—View disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
SEC filing ↗
—View disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
SEC filing ↗
—View disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a sale at CRISPR Therapeutics AG on Oct 14, 2026 valued at $720,373.36.

Review SEC filing
Latest buy

The insider reported a buy at ADARx Pharmaceuticals, Inc. on Sep 28, 2026 valued at $10,074,081.

Review SEC filing

Monthly open-market activity

Last 2 reported months · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
Sep 202630$27,200,000$0+$27,200,000
Oct 202601$0$720,373.36−$720,373.36

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$6.98M
Median P/S size$8.56M
Direct3
Indirect15
Oct 14, 2026exercise

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

No purchases currently have the price observations needed for a 90-day return. This may reflect incomplete price coverage or purchases that have not reached the return window.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

2 observations · Oct 14, 2026 – Oct 14, 2026. Window ends at the latest available report, not today.

Selected observation · Oct 14, 202615,486 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Oct 14, 202630,000Oct 16, 2026View transaction
Oct 14, 202615,486Oct 16, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

George Simeon Insider Activity FAQ

SEC Form 4 context

Who is George Simeon?

George Simeon is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001595117.

Which companies has George Simeon reported transactions for?

CRISPR Therapeutics AG, ADARx Pharmaceuticals, Inc., Odyssey Therapeutics, Inc., Avalyn Pharma Inc.

When was George Simeon's latest insider buy?

The insider reported a buy at ADARx Pharmaceuticals, Inc. on Sep 28, 2026 valued at $10,074,081.

When was George Simeon's latest insider sale?

The insider reported a sale at CRISPR Therapeutics AG on Oct 14, 2026 valued at $720,373.36.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.